Cheraghpour Makan, Askari Masomeh, Tierling Sascha, Shojaee Sajad, Sadeghi Amir, Ketabi Moghadam Pardis, Khazdouz Maryam, Asadzadeh Aghdaei Hamid, Piroozkhah Moein, Nazemalhosseini-Mojarad Ehsan, Fatemi Nayeralsadat
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Genetics/Epigenetics, Faculty NT, Saarland University, Saarbrücken, Germany.
Front Oncol. 2023 May 22;13:1168942. doi: 10.3389/fonc.2023.1168942. eCollection 2023.
The receptors, ligands, and associated proteins of the insulin-like growth factor (IGF) family are involved in cancer development. The receptor and its accompanying signaling cascade are a crucial growth-regulatory mechanism that plays an important role in colorectal cancer (CRC) proliferation and differentiation. (Insulin receptor substrate-1), a major substrate for the , is involved in cell growth and promotes tumorigenesis. There are shreds of evidence from prior research suggesting that system polymorphisms may influence susceptibility to CRC. However, the findings in this area were contradictory. Accordingly, we carried out a systematic literature search to identify all case-control, cross-sectional, and cohort studies on the association between various polymorphisms across four pathway genes (, , , and ) and the risk of CRC.
We performed a comprehensive search strategy in PubMed, Scopus, and Web of Science databases for articles available until Aug 30, 2022. A total of 26 eligible studies with /, and polymorphisms; met the inclusion criteria. All case-control studies for rs6214C>T, rs1801278G>A, and rs1805097G>A comprising 22,084 cases and 29,212 controls were included in the current meta-analysis. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate relationships between the polymorphisms and CRC susceptibility. All statistical analyses were performed using STATA software version 14.0.
The meta-analysis of available data for rs6214C>T, rs1801278G>A, and rs1805097G>A showed a significant association between these polymorphisms and an increased CRC risk in some of the comparisons studied (rs6214C>T, pooled OR for CC = 0.43, 95% CI 0.21- 0.87, P = 0.019; rs1801278G>A, OR for GA = 0.74, 95% CI 0.58-0.94, P = 0.016; rs1805097G>A, OR for GA = 0.83, 95% CI 0.71-0.96, P = 0.013). Nevertheless, the meta-analysis did not include other genetic variations in , and due to heterogeneity and limited sample size.
This systematic review and meta-analysis provide evidence that genetic variants in rs6214C>T, rs1801278G>A, and rs1805097G>A are associated with an increased risk of CRC. These findings may contribute to a better understanding of the complex genetic mechanisms involved in CRC development and could inform future research on prevention and treatment strategies for this disease.
胰岛素样生长因子(IGF)家族的受体、配体及相关蛋白参与癌症发展。该受体及其伴随的信号级联是一种关键的生长调节机制,在结直肠癌(CRC)的增殖和分化中起重要作用。胰岛素受体底物 -1(IRS -1)作为胰岛素受体的主要底物,参与细胞生长并促进肿瘤发生。先前研究有证据表明胰岛素样生长因子系统多态性可能影响CRC易感性。然而,该领域的研究结果相互矛盾。因此,我们进行了系统的文献检索,以确定关于四个胰岛素样生长因子通路基因(IGF -1、IGF -2、IGF -1R和IRS -1)的各种多态性与CRC风险之间关联的所有病例对照研究、横断面研究和队列研究。
我们在PubMed、Scopus和Web of Science数据库中执行了全面的检索策略,以查找截至2022年8月30日可用的文章。共有26项符合条件的研究涉及IGF -1、IGF -2和IRS -1多态性;符合纳入标准。当前的荟萃分析纳入了所有关于rs6214C>T(IGF -1)、rs1801278G>A(IGF -2)和rs1805097G>A(IRS -1)的病例对照研究,包括22,084例病例和29,212例对照。采用合并比值比(OR)及95%置信区间(CI)来评估多态性与CRC易感性之间的关系。所有统计分析均使用STATA软件14.0版进行。
对rs6214C>T(IGF -1)、rs1801278G>A(IGF -2)和rs1805097G>A(IRS -1)现有数据的荟萃分析显示,在某些研究的比较中,这些多态性与CRC风险增加之间存在显著关联(rs6214C>T,CC基因型的合并OR = 0.43,95% CI 0.21 - 0.87,P = 0.019;rs1801278G>A,GA基因型的OR = 0.74,95% CI 0.58 - 0.94,P = 0.016;rs1805097G>A,GA基因型的OR = 0.83,95% CI 0.71 - 0.96,P = 0.013)。然而,由于异质性和样本量有限,荟萃分析未纳入IGF -1、IGF -2和IRS -1中的其他基因变异。
这项系统评价和荟萃分析提供了证据,表明rs6214C>T(IGF -1)、rs1801278G>A(IGF -2)和rs1805097G>A(IRS -1)中的基因变异与CRC风险增加相关。这些发现可能有助于更好地理解CRC发展中涉及的复杂遗传机制,并可为该疾病未来的预防和治疗策略研究提供参考。